U.S. regulators approve new COVID-19 vaccine option
Novavax makes a more traditional type of shot than the three other COVID-19 vaccines available for use in the U.S.—and one that’s already available in Europe and multiple other countries.
Novavax makes a more traditional type of shot than the three other COVID-19 vaccines available for use in the U.S.—and one that’s already available in Europe and multiple other countries.
The surge reversed years of progress fighting one of the gravest public health challenges in modern medicine, according to a new analysis released Tuesday by the Centers for Disease Control and Prevention.
Virus levels have risen across the country, fueled by ever-more-contagious omicron subvariants such as BA. 5 that evade some immune protections and have increased the risk of reinfections.
Officials warn of a possible fall or winter wave—perhaps as many as 100 million infections in the United States—that could again flood hospitals with COVID patients.
The announcement comes as COVID-19 cases, hospitalizations and deaths are rising again, although they remain near their lowest levels since the coronavirus outbreak began in 2020.
The findings by the National Center for Education Statistics, or NCES, based on responses from of leaders at 846 public schools, underline problems that have become increasingly well known during more than two years of pandemic-altered education.
Close to half or more of U.S. adults say they are not likely to attend virtual activities, receive virtual health care, have groceries delivered or use curbside pickup after the coronavirus pandemic is over.
Indianapolis-based Eli Lilly and Co. on Wednesday announced an agreement with the U.S. government to supply an additional 150,000 doses of its COVID-fighting antibody bebtelovimab.
An FDA panel voted 19-2 that COVID-19 boosters should contain some version of the super-contagious omicron variant, to be ready for an anticipated fall booster campaign.
The FDA is considering ordering a recipe change for the vaccines made by both Pfizer and rival Moderna in hopes that modified boosters could better protect against another COVID surge expected this fall and winter.
In a new phase of long-term strategies, businesses can consider a metrics-based approach, lobby legislators and local officials to rely on evidence, provide employees and customers with predictability around mask-wearing, and protect health and business operations.
The researchers used data from 185 countries to estimate that vaccines prevented 4.2 million COVID-19 deaths in India, 1.9 million in the United States, 1 million in Brazil, 631,000 in France and 507,000 in the United Kingdom.
After more than two years of navigating the pandemic much like their K-12 counterparts, directors of child care facilities are hoping parents will take advantage of the new vaccines to protect their children and those around them.
Indianapolis Public Schools has spent around 10% of its $213.5 million in federal COVID-19 funding to date. That figure is low compared to other districts in Indiana and across the country, but IPS officials are preparing to spend the full allocation.
While most carriers are enjoying bumper sales as customers flood back following the lifting of COVID curbs, taking leisure trips and catching up with friends and family, there are doubts about how long the surge will continue as high fuel prices push airlines to hike fares.
The FDA also authorized Moderna’s vaccine for school-aged children and teens. Pfizer’s shots had been the only option for those ages.
An advisory panel for the Food and Drug Administration gave a thumbs-up Wednesday to vaccines from Moderna and Pfizer for children under 5. It’s the only age group not yet eligible for vaccination against the coronavirus.
The SBA’s Office of the Inspector General has estimated that at least $80 billion distributed from the $400 billion Economic Injury Disaster Loan program could have been fraudulent, much of it in scams using stolen identities.
In hospitals across the country, physicians are adjusting protocols that for decades reflected a predictable cycle of illnesses that would come and go when schools closed or the weather changed.
The Food and Drug Administration posted its analysis of the Pfizer shot ahead of a Wednesday meeting where outside experts will vote on whether the shots are ready for the nation’s 18 million babies, toddlers and preschoolers.